Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
NCT Number:
NCT05036226
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx, Esophagus, Colon, Anus, Larynx, Bones and Joints, Corpus Uteri, Other Female Genital, Prostate, Eye and Orbit, Brain and Nervous System, Breast, Cervix Uteri
Study Objectives:
Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
Study Documents
(MUSC NetID required for document access)